Unlike chemoimmunotherapy regimens, which are given for a defined period, ibrutinib, a first-in-class Bruton's kinase inhibitor, allows most patients with CLL to remain on treatment for an extended period. Our experience, supported by sequential CT scan images, suggests that long-term ibrutinib promotes a high response rate that improves in quality with time.
Question
New targeted inhibitors of B-cell receptor, such as ibrutinib, yield remarkable responses in patients with CLL. Does the quality of response gradually improve with duration of treatment?
Discussion
An 83-year-old man with CLL refractory to rituximab and bendamustine presented a massive enlargement of mesenteric lymph nodes without histologic transformation into Richter syndrome.
Continuous oral ibrutinib 420 mg/daily was started. A transient lymphocytosis up to 85 9 10 9 /L after 1 month of therapy was considered to be treatment related [1] . On the other hand, sequential CT scanning demonstrated a progressive shrinkage of the abdominal lymph nodes with the best overall response obtained at 12 months (Fig. 1) . The concomitant minimal residual disease (MRD) negativity in the blood or bone marrow denoted complete response (International Workshop on CLL criteria) [2] . This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
